Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 321-326

  Dover, Anna R ^a   Hadoke, Patrick W F ^a   Walker, Brian R ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Endothelium; Fibrinolysis; Glucocorticoids; Human; Vasodilatation

Indexed keywords

ACETYLCHOLINE; BRADYKININ; GLUCOCORTICOID; HYDROCORTISONE; METYRAPONE; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; SODIUM CHLORIDE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); ENDOTHELIUM; FIBRINOLYSIS; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ACETYLCHOLINE; ADULT; ANTI-INFLAMMATORY AGENTS; BRADYKININ; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FIBRINOLYSIS; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; MALE; METYRAPONE; MIDDLE AGED; NITROPRUSSIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGIONAL BLOOD FLOW; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION;

EID: 34548803089     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180cab148     Document Type: Article

References (50)

1. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313:1315-1322.
2. Cannon CP, McCabe CH, Stone PH, et al. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol. 1997;79:253-258.
3. Muller JE. Circadian variation in cardiovascular events. Am J Hypertens. 1999;12:35S-42S.
4. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989;79:101-106.
5. Kurnik PB. Practical implications of circadian variations in thrombolytic and antithrombotic activities. Cardiol Clin. 1996;14:251-262.
6. Leor J, Poole WK, Kloner RA. Sudden cardiac death triggered by an earthquake. N Engl J Med. 1996;334:413-419.
7. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
8. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859-865.
9. Sartori MT, Patrassi GM, Rigotti P, et al. Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation. 2000;69:2116-2121.
10. Fatti LM, Bottasso B, Invitti C, et al. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest. 2000;23:145-150.
11. Ikkala E, Myllyla G, Pelkonen R, et al. Haemostatic parameters in Cushing's syndrome. Acta Med Scand. 1985;217:507-511.
12. Patrassi GM, Sartori MT, Viero ML, et al. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis. 1992;3:789-793.
13. Sartori TM, Maurizio PG, Sara P, et al. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant. 1999;18:693-700.
14. Uno S, Nakamura M, Ohomagari Y, et al. Regulation of tissue-type plasminogen activator (tPA) and type-1 plasminogen activator inhibitor (PAI-1) gene expression in rat hepatocytes in primary culture. J Biochem (Tokyo). 1998;123:806-812.
15. He G, Pedersen SB, Bruun JM, et al. Regulation of plasminogen activitor inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and estrogen. Horm Metab Res. 2000;32:515-520.
16. Simpson AJ, Booth NA, Moore NR, et al. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol. 1991;44:139-143.
17. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991;88:1346-1353.
18. Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res. 1999;41:55-64.
19. Walker BR, Williams BC. Corticosteroids and vascular tone: mapping the messenger maze. Clin Sci. 1992;82:597-605.
20. Mangos G, Walker BR, Kelly JJ, et al. Cortisol inhibits cholinergic dilatation in the human forearm: towards an explanation for glucocorticoid- induced hypertension. Am J Hypertens. 2000;13:1155-1160.
21. Iuchi T, Akaike M, Mitsui T, et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res. 2003;92:81-87.
22. Labinjoh C, Newby DE, Dawson P, et al. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res. 2000;47:707-714.
23. Labinjoh C, Newby DE, Pellegrini MP, et al. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin- converting enzyme inhibition. J Am Coll Cardiol. 2001;38:1402-1408.
24. Stein CM, Brown N, Vaughan DE, et al. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium- independent agonists in human vasculature. J Am Coll Cardiol. 1998;32:117-122.
25. Brown NJ, Gainer JV, Stein CM, et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999;33:1431-1435.
26. Jern S, Selin L, Bergbrant A, et al. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost. 1994;72:588-594.
27. Newby DE, Wright RA, Ludlam CA, et al. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
28. Newby DE, Wright RA, Dawson P, et al. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res. 1998;38:485-492.
29. Benjamin N, Calver A, Collier J, et al. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918-923.
30. Webb DJ. The pharmacology of human blood vessels in vivo. J Vasc Res. 1995;32:2-15.
31. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol. 2005;25:2470-2479.
32. Declerck PJ, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res Suppl. 1990;10:3-9.
33. Booth NA, Walker E, Maughan R, et al. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood. 1987;69:1600-1604.
34. Whitworth JA, Schyvens CG, Zhang Y, et al. The nitric oxide system in glucocorticoid-induced hypertension. J Hypertens. 2002;20:1035-1043.
35. Jackson RV, Nye EJ, Grice JE, et al. Early rise in blood pressure following administration of adrenocorticotropic hormone-[1-24] in humans. Clin Exp Pharmacol Physiol. 2001;28:773-775.
36. Williamson PM, Kohlhagen JL, Mangos GJ, et al. Acute effects of hydrocortisone on plasma nitrate/nitrite activity and forearm vasodilator responsiveness in normal human subjects. Clin Exp Pharmacol Physiol. 2005;32:162-166.
37. van Uum SH, Hermus AR, Sweep CG, et al. Short-term cortisol infusion in the brachial artery, with and without inhibiting 11 beta-hydroxysteroid dehydrogenase, does not alter forearm vascular resistance in normotensive and hypertensive subjects. Eur J Clin Invest. 2002;32:874-881.
38. Dandona P, Thusu K, Hafeez R, et al. Effect of hydrocortisone on oxygen free radical generation by mononuclear cells. Metabolism. 1998;47:788-791.
39. Broadley AJ, Korszun A, Abdelaal E, et al. Inhibition of cortisol production with metyrapone prevents mental stress-induced endothelial dysfunction and baroreflex impairment. J Am Coll Cardiol. 2005;46:344-350.
40. Chia S, Ludlam CA, Fox KA, et al. Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. J Am Coll Cardiol. 2003;41:333-339.
41. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
42. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 2006;118:247-252.
43. Gelehrter TD, Sznycer-Laszuk R, Zeheb R, et al. Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity: paradoxical induction of both tPA antigen and plasminogen activator inhibitor. Mol Endocrinol. 1987;1:97-101.
44. Udden J, Eriksson P, Hoffstedt J. Glucocorticoid-regulated adipose tissue secretion of PAI-1, but not IL-6, TNFalpha or leptin in vivo. Horm Metab Res. 2002;34:698-702.
45. Fukumoto S, Allan EH, Zeheb R, et al. Glucocorticoid regulation of plasminogen activator inhibitor-1 messenger ribonucleic acid and protein in normal and malignant rat osteoblasts. Endocrinology. 1992;130:797-804.
46. Reinders JH, Kaczmarek P, van Giezen JJ, et al. Regulation of plasminogen activation in rat cell lines. Ann N Y Acad Sci. 1992;667:194-198.
47. Halleux CM, Declerck PJ, Tran SL, et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab. 1999;84:4097-4105.
48. Morange PE, Aubert J, Peiretti F, et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes. 1999;48:890-895.
49. van Giezen JJ, Jansen JW. Correlation of in vitro and in vivo decreased fibrinolytic activity caused by dexamethasone. Ann N Y Acad Sci. 1992;667:199-201.
50. van Giezen JJ, Brakkee JG, Dreteler GH, et al. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul Fibrinolysis. 1994;5:249-255.